Files
Document type
ArticleVersion
Published versionPublication date
All rights reserved
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/171258
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Parkinson's disease (PD) is a common neurodegenerative disease that lacks therapies to prevent progressive neurodegeneration. Impaired energy metabolism and reduced ATP levels are common features of PD. Previous studies revealed that terazosin (TZ) enhances the activity of phosphoglycerate kinase 1 (PGK1), thereby stimulating glycolysis and increasing cellular ATP levels. Therefore, we asked whether enhancement of PGK1 activity would change the course of PD. In toxin-induced and genetic PD models in mice, rats, flies, and induced pluripotent stem cells, TZ increased brain ATP levels and slowed or prevented neuron loss. The drug increased dopamine levels and partially restored motor function. Because TZ is prescribed clinically, we also interrogated 2 distinct human databases. We found slower disease progression, decreased PD-related complications, and a reduced frequency of PD diagnoses in individuals taking TZ and related drugs. These findings suggest that enhancing PGK1 activity and increasing glycolysis may slow neurodegeneration in PD.
Subject (English)
Citation
Citation
CAI, Rong, et al. Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. Journal of Clinical Investigation. 2019. Vol. 129, num. 10, pags. 4539-4549. ISSN 0021-9738. [consulted: 18 of August of 2026]. Available at: https://hdl.handle.net/2445/171258